Bio-Rad Laboratories Net Total Equity Issued/Repurchased 2010-2024 | BIO
Bio-Rad Laboratories annual/quarterly net total equity issued/repurchased history and growth rate from 2010 to 2024. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
- Bio-Rad Laboratories net total equity issued/repurchased for the quarter ending December 31, 2024 was $-0.184B, a 55.05% decline year-over-year.
- Bio-Rad Laboratories net total equity issued/repurchased for the twelve months ending December 31, 2024 was $-0.468B, a 42.86% decline year-over-year.
- Bio-Rad Laboratories annual net total equity issued/repurchased for 2024 was $-0.184B, a 55.05% decline from 2023.
- Bio-Rad Laboratories annual net total equity issued/repurchased for 2023 was $-0.41B, a 107.07% increase from 2022.
- Bio-Rad Laboratories annual net total equity issued/repurchased for 2022 was $-0.198B, a 574.59% increase from 2021.
| Bio-Rad Laboratories Annual Net Total Equity Issued/Repurchased (Millions of US $) |
|
|---|---|
| 2024 | $-184 |
| 2023 | $-410 |
| 2022 | $-198 |
| 2021 | $-29 |
| 2020 | $-80 |
| 2019 | $-11 |
| 2018 | $-35 |
| 2017 | $12 |
| 2016 | $11 |
| 2015 | $8 |
| 2014 | $15 |
| 2013 | $11 |
| 2012 | $11 |
| 2011 | $14 |
| 2010 | $13 |
| 2009 | $10 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $6.735B | $2.567B |
| Bio-Rad Laboratories is a manufacturer and global supplier of clinical diagnostics and life science research products in the healthcare, analytical chemistry life science research and other markets. It offers a wide portfolio of products and systems which allow the separation of complex chemical and biological materials and discovery, analysis and purification of their components. Bio-Rad has extensive and direct distribution channels outside the United States through subsidiaries which focus on sales, customer service and product distribution. The company operates through two reportable segments - Life Science segment which designs, manufactures, markets and services reagents, apparatus and instruments utilized for biological research. Clinical Diagnostics - This business markets and distributes products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians office laboratories, transfusion laboratories as well as insurance and forensic testing laboratories. | |||